Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients

被引:11
|
作者
Czarnecka, D. [1 ]
Koch, E. M. W. [1 ]
Gottwald-Hostalek, U. [1 ]
机构
[1] Merck KGaA, D-64293 Darmstadt, Germany
关键词
Adherence; Amlodipine; Antihypertensive therapy; Bisoprolol; Fixed-dose combination; SAFETY;
D O I
10.1185/03007995.2015.1027676
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The study objective was assessing patient adherence to a fixed-dose combination (FDC) of bisoprolol and amlodipine in daily practice in patients who had been switched from the free to the fixed-dose combination prior to recruitment. Material and methods: The non-investigational study was carried out in Poland. Patients over 18 years of age with essential hypertension were recruited if they had already been switched from a free combination to the FDC at least 4 weeks prior to recruitment. Exclusion criteria included pregnancy, lactation, any contraindication to the FDC, and other antihypertensive treatment. Adherence was measured by tablet count (tablets taken divided by tablets prescribed, times 100) and defined as follows: excellent >90%, good 76-90%, moderate 51-75%, bad <= 50%. Other patient data, clinical findings and laboratory values were recorded upon availability at study start, after 3 months (voluntary) and after 6 months. Results: Data of 4288 patients (mean age: 59 years; gender: 50% each) were documented. The average daily doses of the FDC were 5.8 mg bisoprolol and 6.4 mg amlodipine. These doses differ only slightly from those of the free combination. After 3 months' treatment with the FDC, a dose increase was carried out in 113 patients for bisoprolol and in 126 for amlodipine. After 6 months of FDC treatment, 82% of the participants of the study showed excellent adherence and for a further 15% the adherence could be considered good. This strong adherence may have led to the observed reduction in systolic and diastolic blood pressure of 11% (Cohen's D efficient size 1.23). In addition, pulse pressure decreased from 58.8mm to 52.2 mm. Also in diabetic patients (21% of the cohort), further reduction of systolic blood pressure values could be achieved (mean before 150 mm, after 133), wherein the initial differences compared to patients without diabetes had disappeared. The pulse rate also changed from 75 b/min to 68 b/min under the FDC. Conclusion: These study results clearly show that the FDC leads to excellent patient adherence and therefore may result in better blood pressure control. Blood pressure control is crucial in the risk reduction of cardiovascular events. The key limitation of this study is that the study design does not allow a direct comparison of patient adherence under the free and the fixed-dose combination.
引用
收藏
页码:875 / 881
页数:7
相关论文
共 50 条
  • [21] Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia
    Lin, Chia-Pin
    Tung, Ying-Chang
    Hsiao, Fu-Chih
    Yang, Chia-Hung
    Kao, Yi-Wei
    Lin, Yu-Sheng
    Chu, You-Chia
    Chu, Pao-Hsien
    JOURNAL OF CLINICAL HYPERTENSION, 2020, 22 (10): : 1846 - 1853
  • [22] Clinical Benefit of Fixed-Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia
    Lin, Chia-Pin
    Hsu, Tzyy-Jer
    Tung, Ying-Chang
    Hsiao, Fu-Chih
    Chou, Shing-Hsien
    Lin, Yu-Sheng
    Chen, Shao-Wei
    Chu, Pao-Hsien
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (09):
  • [23] Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension
    Lin, Tsung-Hsien
    Tsai, Cheng-Dao
    Pan, Ju-Pin
    Hou, Charles Jia-Yin
    Hsia, Chien-Hsun
    Tsai, Jui-Peng
    Lai, Wen-Ter
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2013, 29 (05): : 265 - 270
  • [24] Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension
    Paton, D. M.
    DRUGS OF TODAY, 2017, 53 (01) : 19 - 26
  • [25] Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension
    Sander, Gary E.
    Giles, Thomas D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 763 - 770
  • [26] Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice
    Bramlage, Peter
    Fronk, Eva-Maria
    Wolf, Wolf-Peter
    Smolnik, Ruediger
    Sutton, Gemma
    Schmieder, Roland E.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 1 - 8
  • [27] Optimization of treatment in hypertensive patients in real clinical practice: Role of a fixed-dose perindopril A and amlodipine combination (Results of the Russian observational CONSTANTA trial)
    Kobalava, Zh D.
    Kotovskaya, Yu V.
    Khodorovich, N. A.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (03) : 66 - 70
  • [28] Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial
    Wang, Kang-Ling
    Yu, Wen-Chung
    Lu, Tse-Min
    Chen, Lung-Ching
    Leu, Hsin-Bang
    Chiang, Chern-En
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (10) : 900 - 905
  • [29] TRIPLE-DRUG, FIXED-DOSE COMBINATIONS FOR THE TREATMENT OF HYPERTENSION: FOCUS ON OLMESARTAN/AMLODIPINE/HYDROCHLOROTHIAZIDE COMBINATION
    Chrysant, S. G.
    DRUGS OF TODAY, 2011, 47 (03) : 197 - 206
  • [30] Hypertensive patients' adherence, motivation, and awareness during fixed-dose perindopril A and amlodipine combination treatment (Results of the CONSTANTA trial)
    Kotovskaya, Yu. V.
    Villevalde, S. V.
    Tigai, Zh G.
    Kobalava, Zh D.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (02) : 64 - 69